Role of taxanes in advanced prostate cancer
| Autor: | J. Cassinello, L. M. Antón Aparicio, J. Carballido Rodríguez |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Cancer Research medicine.medical_specialty Programmed cell death medicine.drug_class Docetaxel Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine AR splice variant Internal medicine medicine Animals Humans Enzalutamide Cabazitaxel business.industry Prostatic Neoplasms General Medicine medicine.disease Androgen Androgen receptor 030104 developmental biology Endocrinology Oncology chemistry 030220 oncology & carcinogenesis Localized disease Cancer research Taxoids business medicine.drug |
| Zdroj: | RUC. Repositorio da Universidade da Coruña instname |
| Popis: | [Abstract] Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the evolution of the disease. The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the increasing role of taxanes at earlier states of prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|